KAROLINSKA INSTITUTET

Their core work

Karolinska Institutet is one of Europe's leading medical universities, specializing in biomedical and clinical research spanning cancer biology, neuroscience, epidemiology, and personalized medicine. With nearly 300 H2020 projects and close to EUR 200 million in EC funding, they serve as a major hub for translational health research — turning laboratory discoveries into clinical applications. Their work covers the full spectrum from molecular-level studies (genomics, epigenetics, chromatin biology) to population-level health assessments (risk stratification, disease prevention, ageing), with growing strength in computational and data-driven approaches to medicine.

What they specialise in

How they've shifted over time

In the early H2020 period (2015-2018), Karolinska focused heavily on classical epidemiology, genomics, children's health, and infrastructure projects like e-science platforms — reflecting a broad, foundational research portfolio. By the later period (2019-2021), there was a clear pivot toward data-driven and precision approaches: personalized medicine, metabolomics, machine learning, and biobanking became dominant themes, while inflammation and microbiome research emerged as new strengths. This evolution shows a university moving from traditional biomedical research toward computational, multi-omics medicine with stronger clinical translation ambitions.

Karolinska is rapidly building capacity at the intersection of AI/machine learning, multi-omics data, and clinical medicine — expect future projects to center on computational biomedicine and large-scale biobank analytics.

How they like to work

Karolinska operates predominantly as an active partner (193 projects as participant vs 94 as coordinator), but their 32% coordination rate is remarkably high for a university, indicating strong project leadership capability. With 1,832 unique consortium partners across 77 countries, they function as a major European research hub with an exceptionally wide and diverse network. Their presence across RIA (134 projects) and MSCA training networks (42 projects) shows they balance frontier research with a strong commitment to training the next generation of researchers.

Karolinska has collaborated with 1,832 unique partners across 77 countries, making them one of the most connected medical research institutions in H2020. Their network spans all of Europe with notable reach into Africa (B3Africa, Sci-GaIA) and global health contexts (SMART2D), extending well beyond the typical Nordic collaboration cluster.

What sets them apart

Karolinska combines world-class clinical medicine (as a university hospital-affiliated institution) with deep computational biology capabilities and one of Europe's most extensive biobanking infrastructures. Unlike purely clinical or purely computational research groups, they bridge wet-lab molecular research, population-scale epidemiology, and machine learning under one roof. For consortium builders, they bring not just scientific excellence but also access to Swedish patient cohorts, Nordic biobank data, and a proven track record of managing large multi-country projects.

Highlights from their portfolio

• Allelic Regulation
  EUR 1.9M ERC-level coordinator grant on single-cell gene expression — represents Karolinska's frontier genomics capability.
• EDC-MixRisk
  EUR 1.1M coordinated project integrating epidemiology with experimental biology for chemical mixture risk assessment — exemplifies their translational, cross-disciplinary strength.
• SMART2D
  Nearly EUR 1M coordinated project on diabetes self-management in low-resource settings — shows their global health reach beyond typical European medical research.